Expression and function of HLA-DR3 and DQ8 in transgenic mice lacking functional H2-M

Tissue Antigens

Volumn 62, Issue 2, 2003, Pages 149-161

  Rajagopalan, G ^a   Smart, M K ^a   Cheng, S ^a   Krco, C J ^a   Johnson, K L ^b   David, Chella S ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antigen presentation processing; HLA; MHC; Transgenic knockout

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; HLA DQ ANTIGEN; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HLA SYSTEM; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS; CELL DIVISION; ENTEROTOXINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DQ ANTIGENS; HLA-DR3 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDES; SHOCK, SEPTIC; SUPERANTIGENS; T-LYMPHOCYTES;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS MUSCULUS;

EID: 0042697138     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2003.00088.x     Document Type: Article

References (52)

1. Pieters J. MHC class II-restricted antigen processing. and Presentation. Adv Immunol 2000: 75: 159-208.
2. Busch R, Doebele RC, Patil NS, Pashine A, Mellins ED. Accessory molecules for MHC class II peptide loading. Curr Opin Immunol 2000: 12: 99-106.
3. Bertolino P, Rabourdin-Combe C. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to. Cd4+ T Cells. Crit Rev Immunol 1996: 16: 359-79.
4. Alfonso C, Karlsson L, Nonclassical MHC class II molecules. Annu Rev Immunol 2000: 18: 113-42.
5. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR Molecules. J Exp Med 1996: 184: 2153-65.
6. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBOJ 1996: 15: 6144-54.
7. Arndt SO, Vogt AB, Hammerling GJ, Kropshofer H. Selection of the MHC class II-associated peptide repertoire by HLA-DM. Immunol Res 1997: 16: 261-72.
8. Ullrich HJ, Doring K, Gruneberg U, Jahnig F, Trowsdale J, van Ham SM. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc Natl Acad Sci U S A 1997: 94: 13163-8.
9. Brocke P, Garbi N, Momburg F, Hammerling GJ. HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol 2002: 14: 22-9.
10. Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol 2002: 169: 5109-17.
11. Fung-Leung WP, Surh CD, Liljedahl M et al. antigen presentation T-cell development H2-M-deficient mice. Sci 1996: 271: 1278-81.
12. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T-cell repertoire sdection. Cell 1996: 84: 543-50.
13. Miyazaki T, Wolf P, Tourne S et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996: 84: 531-41.
14. Bikoff EK, Wutz G, Kenty GA, Koonce CH, Robertson EJ. Relaxed DM requirements during class II peptide loading and CD4+ T-call maturation in BALB/c mice. J Immunol 2001: 166: 5087-98.
15. Brooks AG, Campbell PL, Reynolds P, Gautam AM, McCluskey J. Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM Genes. J Immunol 1994: 153: 5382-92.
16. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2Mdeficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol 1998: 28: 2605-18.
17. Swier K, Brown DR, Bird JJ, Martin WD, Van Kaer L, Reiner SL. A critical, invariant chain-independent role for H2-M in antigen presentation. J Immunol 1998: 160: 540-4.
18. Alfonso C, Han JO, Williams GS, Karlsson L. The impact of H2-DM on humoral immune responses. J Immunol 2001: 167: 6348-55.
19. Slavin AJ, Soos JM, Stuve O et al. Requirement for endocytic antigen processing influence invariant chain H-2M deficiencies cns autoimmunity. J Clin Invest 2001: 108: 1133-9.
20. Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmtme encephalomyelitis. J Immunol 2002: 168: 4173-83.
21. Kenty G, Martin WD, Van Kaer L, Bikoff EK. MHC class II expression in double mutant mice lacking invariant chain and DM Functions. J Immunol 1998: 160: 606-14.
22. Kovats S, Grubin CE, Eastman S et al. invariant chain-independent function H-2m formation endogenous peptide-major histocompatibility complex class ii complexes vivo. J Exp Med 1998: 187: 245-51.
23. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992: 360: 474-7.
24. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 Cells. Immunity 1994: 1: 595-606.
25. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995: 82: 155-65.
26. Serradell L, Muntasell A, Catalfamo M et al. HLA-DM can partially replace invariant chain for HLA-DR transport surface expression transfected endocrine epithelial cells. Tissue Antigens 1999: 53: 447-58.
27. Vogt AB, Kropshofer H, Moldenhauer G, Hammerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci U S A 1996: 93: 9724-9.
28. Patil NS, Pashine A, Belmares MP et al. Rheumatoid arthritis (RA) -associated HLA-DR alleles form less stable complexes with class ii-associated invariant chain peptide than non-RA-associated HLA-DR alleles. J Immunol 2001: 167: 7157-68.
29. Ettinger RA, Liu AW, Nepom GT, Kwok WW. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. J Immunol 1998: 161: 6439-45.
30. Awa RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994: 1: 763-74.
31. Kropshofer H, Arndt SO, Moldenhauer G, Hammerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997: 6: 293-302.
32. Kropshofer H, Vogt AB, Stern LJ, Hammerling GJ. Self-release of CLIP in peptide loading of HLA-DR Molecules. Sci 1995: 270: 1357-9.
33. Rajagopalan G, Smart MK, Krco CJ, David CS. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain. J Immunol 2002: 169: 1774-83.
34. Nabozny GH, Baisch JM, Cheng S et al. HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J Exp Med 1996: 183: 27-37.
35. Kong YC, Lomo LC, Motte RW et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA- DRB1*0301 (DR3) Gene. J Exp Med 1996: 184: 1167-72.
36. Verreck FA, Fargeas CA, Hammerling GJ. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM. Eur J Immunol 2001: 31: 1029-36.
37. Ovsyannikova IG, Johnson KL, Naylor S, Poland GA. Isolation and rapid identification of an abundant self-peptide from class II HLADRB1*0401 alleles induced by measles vaccine virus infection. J Immunol Meth 2000: 246: 1-12.
38. Krco CJ, Watanabe S, Harders J, Griffths MM, Luthra H, David CS. Identification of T-cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. J Immunol 1999: 163: 1661-5.
39. Kudva YC, Rajagopalan G, Raju R et al. Modulation insulitis type 1 diabetes transgenic HLA-Dr3 Dq8 NOD mice lacking endogenous MHC class II. Hum Immunol 2002: 63: 987.
40. Wen L, Wong FS, Burkly L et al. Induction insulitis glutamic acid decarboxylase peptide-specific HLA-DQ8-restricted CD4 (+) T cells from human DQ transgenic mice. J Clin Invest 1998: 102: 947-57.
41. Singh N, Van Kaer L. Unexpected reactivities of T cells selected by a single MHC-peptide ligand. J Immunol 1999: 163: 3583-91.
42. Krakauer T. Immune response to staphylococcal superantigens. Immunol Res 1999: 20: 163-73.
43. Wen R, Cole GA, Surman S, Blackman MA, Woodland DL. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T Cells. J Exp Med 1996: 183: 1083-92.
44. Ghumman B, Bertram EM, Watts TH. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM. sufficient antigen- presenting cells and enhance IgG2a production in vivo. J Immunol 1998: 161: 3262-70.
45. Albert LJ, Denzin LK, Ghumman B, Bangia N, Cresswell P, Watts TH. Quantitative defect in staphylococcal enterotoxin A binding and presentation by HLA-DM-deficient T2. Ak cells corrected transfection HLA-DM Genes. Cell Immunol 1998: 183: 42-51.
46. Tourne S, Miyazaki T, Oxenius A et al. Selection a broad repertoire Cd4+ T cells H-2Ma0/0 mice. Immunity 1997: 7: 187-95.
47. Golovkina T, Agafonova Y, Kazansky D, Chervonsky A. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens. J Immunol 2001: 166: 2244-50.
48. Hogan RJ, VanBeek J, Broussard DR, Surman SL, Woodland DL. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin 1 to T cells. J Immunol 2001: 166: 6514-22.
49. Lavoie PM, Thibodeau J, Cloutier I, Busch R, Sekaly RP. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM. Proc Natl Acad Sci U S A 1997: 94: 6892-7.
50. Langlois MA, Etongue-Mayer P, Ouellette M, Mourad W. Binding of Mycoplasma arthritidis-derived mitogen to human MHC class II molecules via its N terminus is modulated by invariant chain expression and its C terminus is required for T-cell activation. Eur J Immunol 2000: 30: 1748-56.
51. Rajagopalan G, Smart MK, Marietta EV, David CS. Staphylococcal enterotoxin B-induced activation and concomitant resistance to cell death in CD28 deficient HLA-DQ8 transgenic mice. Int Immunol 2002: 14: 801-12.
52. Woodland DL, Wen R, Blackman MA. Why do superantigens care about peptides? Immunol Today 1997: 18: 18-22.